Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors

Atherosclerosis

Volumn 167, Issue 1, 2003, Pages 73-79

  Saito, Mayumi ^a   Ishimitsu, Toshihiko ^a   Minami, Junichi ^a   Ono, Hidehiko ^a   Ohrui, Masami ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

C reactive protein; Dyslipidemia; Hypertension; Obesity; Smoking

Indexed keywords

C REACTIVE PROTEIN; PLASMA PROTEIN;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OBESITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEX DIFFERENTIATION; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE DISTRIBUTION; AGED; ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROBABILITY; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SMOKING;

EID: 0037371135     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00380-5     Document Type: Article

References (46)

1. Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med. 340:1999;115-126.
2. Ridker P.M., Cushman M., Stampfer M.J., Tracy R., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl. J. Med. 336:1997;973-979.
3. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl. J. Med. 342:2000;836-843.
4. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 144:1996;537-547.
5. Haverkate F., Thompson S.G., Pyke S., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 349:1997;462-466.
6. Izzo C., Grillo F., Murador E. Improved method for determination of high-density-lipoprotein cholesterol I. Isolation of high-density lipoproteins by use of polyethylene glycol 6000. Clin. Chem. 27:1981;371-374.
7. Teppo A.M. Immunoturbidimetry of albumin and immunoglobulin G in urine. Clin. Chem. 28:1982;1359-1361.
8. Kannel W.B., Neaton J.D., Wentworth D., Thomas H.E., Stamler J., Hulley S.B., Kjelsberg M.O. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am. Heart J. 112:1986;825-836.
9. Manson J.E., Tosteson H., Ridker P.M., Satterfield S., Hebert P., O'Connor G.T., Buring J., Hennekens C.H. The primary prevention of myocardial infarction. New Engl. J. Med. 326:1992;1406-1416.
10. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. New Engl. J. Med. 337:1997;1360-1369.
11. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
12. Maseri A. Inflammation, atherosclerosis, and ischemic events - exploring the hidden side of the moon. New Engl. J. Med. 336:1997;1014-1016.
13. Carr S.C., Farb A., Pearce W.H., Virmani R., Yao J.S. Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery. 122:1997;757-763.
14. Pasterkamp G., Schoneveld A.H., van der Wal A.C., Hijnen D.J., van Wolveren W.J., Plomp S., Teepen H.L., Borst C. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler. Thromb. Vasc. Biol. 19:1999;54-58.
15. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., Hutchinson W.L., Pepys M.B. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242.
16. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J.R., Pepys M.B. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J. 321:2000;199-204.
17. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 97:1998;425-428.
18. Ferrannini E., Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am. Heart J. 121:1991;1274-1282.
19. Reaven G.M. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am. Heart J. 121:1991;1283-1288.
20. Ferrari P., Weidmann P., Shaw S., Giachino D., Riesen W., Allemann Y., Heynen G. Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am. J. Med. 91:1991;589-596.
21. Imhof A., Froehlich M., Brenner H., Boeing H., Pepys M.B., Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet. 357:2001;763-767.
22. McClain C.J., Barve S., Deaciuc I., Kugelmas M., Hill D. Cytokines in alcoholic liver disease. Semin. Liver Dis. 19:1999;205-219.
23. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 100:1999;230-235.
24. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
25. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. J. Am. Med. Assoc. 282:1999;2131-2135.
26. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19:1999;972-978.
27. Macy E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin. Chem. 43:1997;52-58.
28. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
29. Torzewski M., Rist C., Mortensen R.F., Zwaka T.P., Bienek M., Waltenberger J., Koenig W., Schmitz G., Hombach V., Torzewski J. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20:2000;2094-2099.
30. McCarty M.F. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med. Hypoth. 52:1999;465-477.
31. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 148:2000;209-214.
32. Papanicolaou D.A., Wilder R.L., Manolagas S.C., Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128:1998;127-137.
33. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772.
34. Biasucci L.M., Vitelli A., Liuzzo G., Altamura S., Caligiuri G., Monaco C., Rebuzzi A.G., Ciliberto G., Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation. 94:1996;874-877.
35. Biasucci L.M., Liuzzo G., Fantuzzi G., Caligiuri G., Rebuzzi A.G., Ginnetti F., Dinarello C.A., Maseri A. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 99:1999;2079-2084.
36. Sothern R.B., Roitman-Johnson B., Kanabrocki E.L., Yager J.G., Roodell M.M., Weatherbee J.A., Young M.R., Nenchausky B.M., Scheving L.E. Circadian characteristics of circulating interleukin-6 in men. J. Allergy Clin. Immunol. 95:1995;1029-1035.
37. Meier-Ewert H.K., Ridker P.M., Rifai N., Price N., Dinges D.F., Mullington J.M. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin. Chem. 47:2001;426-430.
38. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 351:1998;1755-1762.
39. Devaraj S., Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic. Biol. Med. 29:2000;790-792.
40. Pryor W.A. Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic. Biol. Med. 28:2000;141-164.
41. Jialal I., Devaraj S. Vitamin E supplementation and cardiovascular events in high-risk patients. New Engl. J. Med. 342:2000;1917-1918.
42. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
43. Ross S.D., Allen I.E., Connelly J.E., Korenblat B.M., Smith M.E., Bishop D., Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch. Intern. Med. 159:1999;1793-1802.
44. Tchernof A., Nolan A., Sites C.K., Ades P.A., Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 105:2002;564-569.
45. Smith J.K.D.R., Douglas J.E., Krishnaswamy G., Berk S. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. J. Am. Med. Assoc. 281:1999;1722-1727.
46. Manson J.E., Hu F.B., Rich-Edwards J.W., Colditz G.A., Stampfer M.J., Willett W.C., Speizer F.E., Hennekens C.H. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. New Engl. J. Med. 341:1999;650-658.